News 21 May 2026

Sera Prognostics Moves Up 15% Just Ahead of Holiday
····

Sera Prognostics Moves Up 15% Just Ahead of Holiday

Sera Prognostics shares jumped 15% to $2.07 Friday, trading over 530,000 shares—21 times the previous day’s volume—despite no new company disclosures. The move outpaced peers and came as Sera reported $14,000 in Q1 revenue, a net loss of $8.4 million, and $86.8 million in cash. Executives said 2026 revenue may stay “modest and uneven” as reimbursement and awareness efforts continue.
May 23, 2026
Cipher Digital Stock Is Jumping Again — The AI Power Bet Behind CIFR’s Rally
···

Cipher Digital Stock Is Jumping Again — The AI Power Bet Behind CIFR’s Rally

Cipher Digital Inc. shares jumped 6.4% to $20.73 Thursday morning, outpacing a weaker tech market as the company pivots from bitcoin mining to AI data-center infrastructure. Trading volume reached 8.5 million shares, with a market value near $8.4 billion. Morgan Stanley raised its price target to $42.50 this week. Cipher reported $35 million in Q1 revenue and negative adjusted EBITDA of $48 million.
May 21, 2026
Canaan Stock Drops After Q1 Loss Widens — Why CAN Is Under Pressure Now
···

Canaan Stock Drops After Q1 Loss Widens — Why CAN Is Under Pressure Now

Canaan shares fell 5.3% to $0.4127 in late-morning Nasdaq trading Thursday after the company reported a first-quarter net loss of $88.7 million and forecast weaker Q2 revenue of $35 million to $45 million. First-quarter revenue dropped to $62.7 million from $196.3 million in the prior quarter. Trading volume reached 3.8 million shares. Several bitcoin-mining peers rose.
May 21, 2026
NCS Multistage Shares Tick Up on Tuesday
···

NCS Multistage Shares Tick Up on Tuesday

NCS Multistage traded at $44.10 in early Nasdaq action Thursday, up about 1% on thin volume of 2,120 shares. The Houston oilfield-services firm reported Q1 revenue of $45.6 million, down from $50 million a year earlier, with a net loss of $0.4 million. U.S. revenue doubled while Canadian sales dropped sharply. No new company news drove the move.
May 21, 2026
RADX Shares Slip Ahead of Cancer-Imaging Update
···

RADX Shares Slip Ahead of Cancer-Imaging Update

Radiopharm Theranostics’ U.S.-listed shares last traded at $4.52, down 1.3% on volume of 325, as investors awaited new data from its lead cancer-imaging program. The company’s most recent update was a May 14 Zacks report, with topline Phase 2 trial results for RAD101 expected around the end of June. Radiopharm reported A$19.2 million in cash as of March 31.
May 21, 2026
PRCT rises as Wall Street slips; investors look again at Aquablation
···

PRCT rises as Wall Street slips; investors look again at Aquablation

PROCEPT BioRobotics shares rose 0.6% to $28.29 in early Thursday trading, outperforming broader medical device stocks as Wall Street opened lower. The move follows the American Urological Association’s strengthened recommendation for Aquablation therapy. PROCEPT reported Q1 revenue of $83.1 million, up 20%, but posted a wider net loss of $31.6 million. The company reaffirmed 2026 revenue guidance of $390–$410 million.
May 21, 2026
Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
···

Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders

Bright Minds Biosciences shares jumped 11.1% to $82.78 after Piper Sandler raised its price target to $220 and reiterated an “Overweight” rating. The company reported C$309.7 million in cash at March 31, up from C$82.9 million in September, and a wider net loss. Lead drug BMB-101 completed Phase 1 and reported Phase 2 data for epilepsy and absence seizures.
May 21, 2026
Spark I gets Nasdaq notice ahead of Kneron deadline
····

Spark I gets Nasdaq notice ahead of Kneron deadline

Spark I Acquisition Corp disclosed it fell below Nasdaq’s minimum 400-holder requirement, triggering a compliance notice received May 14. Shares closed Wednesday at $12.40, about 8.9% above redemption value, with a $107.37 million market cap. The company has 45 days to submit a compliance plan and is negotiating a merger with Kneron Holding Corporation. Spark reported no revenue and a $94,195 net loss for Q1.
May 21, 2026
Bio-Techne Shares Bounce, Investors Eye a Key Risk
···

Bio-Techne Shares Bounce, Investors Eye a Key Risk

Bio-Techne closed Wednesday at $46.70, up 2.7%, marking a three-day rebound but still 35% below its January high. Fiscal third-quarter revenue fell 2% to $311.4 million, missing Wall Street estimates as weak biotech demand and U.S. academic funding cuts weighed on sales. CEO Kim Kelderman described the academic market as “frail” and not on a clear recovery path. Bio-Techne owns 20% of Wilson Wolf and may acquire the rest.
May 21, 2026
Aterian Moves Lower Pre-Market With $18 Million Ballot Ahead
···

Aterian Moves Lower Pre-Market With $18 Million Ballot Ahead

Aterian shares fell 2.5% to $1.15 in premarket trading Thursday after a May 15 filing showed a wider first-quarter loss and raised “substantial doubt” about its ability to continue. The company is seeking stockholder approval to sell major brands for $18 million and issue $7 million in preferred stock, moves that could give investor David E. Lazar control of over 95% of the company.
May 21, 2026
Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
···

Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data

Vanda Pharmaceuticals shares fell 0.5% to $6.15 in premarket trading Thursday, trimming part of Wednesday’s 3.2% gain. First-quarter net product sales rose 3% to $51.7 million, but the company posted a $48.6 million net loss and used $50.2 million in operating cash. Vanda raised 2026 revenue guidance to $240–$290 million, expecting Nereus to contribute up to $30 million this year.
May 21, 2026
LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News
···

LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News

Liminatus Pharma agreed to acquire InnocsAI in an all-stock deal, issuing 1.6 billion shares at $0.20 each—over 35 times its current share count. LIMN rose 51% to $0.2844 in premarket trading. The deal would add CAR-T cancer therapy assets, including a candidate authorized for a Phase 1/2a study in South Korea. Liminatus reported $1.91 million in cash and warned of “substantial doubt” about its ability to continue.
May 21, 2026
Cintas Stock Just Lost Its Rebound — Why CTAS Traders Are Watching the UniFirst Deal
····

Cintas Stock Just Lost Its Rebound — Why CTAS Traders Are Watching the UniFirst Deal

Cintas shares closed Wednesday at $171.36, down 0.49%, after giving back gains from a 3.68% jump Monday. The stock lagged the S&P 500, which rose 1.1% the same day. Investors are watching Cintas’ pending $5.5 billion UniFirst acquisition and projected $375 million in cost synergies. Cintas reported fiscal Q3 revenue of $2.84 billion, up 8.9%, and raised its full-year outlook.
May 21, 2026
Aimei Health: Nasdaq Sends AFJK 60-Day Notice
···

Aimei Health: Nasdaq Sends AFJK 60-Day Notice

Aimei Health received a Nasdaq deficiency notice after missing the May 15 deadline for its March-quarter 10-Q filing. Shares traded at $42.18 in pre-market activity ahead of Thursday’s U.S. session. The company has 60 days from the May 19 notice to regain compliance or risk delisting. Aimei is also seeking to complete a merger with United Hydrogen Group, pending regulatory approval.
May 21, 2026
NMFC Stock Moves Higher Ahead of Open as New Mountain Finance Buyback Faces Private Credit Trial
···

NMFC Stock Moves Higher Ahead of Open as New Mountain Finance Buyback Faces Private Credit Trial

New Mountain Finance Corp. closed Wednesday at $8.12, about 26% below its March 31 net asset value of $10.92 per share. The company reported Q1 adjusted net investment income of $32.2 million and declared a 25-cent quarterly distribution. NMFC cut statutory debt-to-equity to 1.12 times and completed a $470 million portfolio sale. Analysts’ average price target stands at $8.54, with most holding a neutral view.
May 21, 2026
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
···

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear

Neurogene Inc. shares closed at $26.95 Wednesday, up 0.3%, with little movement before Thursday’s Nasdaq open. About 90% of participants have been dosed in the registrational Embolden trial for NGN-401, with completion expected in Q2. Neurogene reported $243.2 million in cash as of March 31, enough to fund operations into early 2028. The company’s latest filings were posted May 12, with no new updates since.
May 21, 2026
1 … 5 6 7 8 9 … 337

Stock Market Today

  • Northern Star Resources (ASX:NST) Valuation Review Amid CEO Succession and Recent Share Decline
    May 23, 2026, 2:06 AM EDT. Northern Star Resources (ASX:NST) announced that Managing Director Stuart Tonkin will step down in early FY27, triggering a formal CEO succession process. The stock has fallen 17.41% over 30 days and 33.53% over 90 days to A$18.83, despite a 5-year shareholder return of 86.28%. Analyst consensus values the stock at A$27.38, indicating a potential 31.2% undervaluation. The recent acquisition and development of the Hemi project and a robust 10-year reserve-backed production profile support long-term growth prospects. However, risks remain from reliance on large capital projects and commodity price volatility. Investors are advised to consider both risks and rewards before making investment decisions.